Related Experiment Video
Updated: May 3, 2026
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
[Atrial fibrillation-pharmacological therapy for rate and rhythm control]
1Klinik für Kardiologie, Stadtspital Triemli, Zürich.
Insights
Effective atrial fibrillation management involves preventing blood clots with anticoagulants and controlling heart rate or rhythm. For persistent symptoms, catheter ablation may be necessary when medications are insufficient.
Area of Science:
- Cardiology
- Pharmacology
- Electrophysiology
Context:
- Atrial fibrillation (AF) management requires a multi-faceted approach.
- Oral anticoagulants are crucial for preventing stroke and mortality in at-risk patients.
- Pharmacological agents like beta-blockers and calcium channel blockers aid in rate control.
Purpose:
- To outline the therapeutic strategies for managing atrial fibrillation.
- To discuss the roles of anticoagulation, rate control, and rhythm control.
- To highlight the limitations of antiarrhythmic drugs and the utility of catheter ablation.
Summary:
- Therapeutic management of atrial fibrillation (AF) focuses on thromboembolism prevention, rate control, and rhythm control.
- Anticoagulants are vital for stroke prevention in patients with risk factors.
- While rate control is often achieved pharmacologically, symptomatic patients may require rhythm control strategies, including antiarrhythmic drugs or catheter ablation due to drug limitations.
Impact:
- Informs clinical decision-making for atrial fibrillation treatment.
- Emphasizes the importance of personalized therapeutic strategies.
- Underscores the growing role of invasive procedures like catheter ablation for refractory cases.
Abstract:
The therapeutic management of patients with atrial fibrillation is based on the three pillars (1) prevention of thromboembolism, (2) rate control, and (3) rhythm control. Patients with one or more risk factors should be treated with an oral anticoagulants in order to prevent stroke and to reduce mortality. The goals of rate control, prevention of heart failure and alleviation of atrial fibrillation related symptoms, normally can be achieved by pharmacological agents slowing the conduction in the AV node (e. g. β-blockers, calcium channel blockers, digoxin). For patients remaining symptomatic despite sufficient rate control adding a rhythm control strategy may be considered. The currently available antiarrhythmic drugs (e. g. flecainide, propafenone, sotalol, dronedarone, amiodarone) are characterized by a rather low efficacy in maintaining sinus rhythm and various possibly life threatening side effects. Therefore, invasive therapies as catheter ablation are frequently needed to achieve rhythm control in symptomatic patients with atrial fibrillation.
Related Concept Videos
01:25Dysrhythmias VI: Management of Dysrhythmias
01:25ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
01:29Disturbances in Heart Rhythm
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...